Barden, Markus and Holzinger, Astrid and Abken, Hinrich (2025) CAR T cells in solid tumors: resistance mechanisms. SPRINGER MEDIZIN VERLAG GmBH, Berlin.
Full text not available from this repository. (Request a copy)Abstract
Background: Chimeric antigen receptor (CAR) T cell treatment is based on the concept of specifically targeting the patient's cytolytic T cells against tumors using a synthetic receptor signaling molecule (CAR). Objective: While CAR T cells show unprecedented efficacy against hematological neoplasms, CAR T cell treatment of solid tumors has so far been largely disappointing, with causes still being only partially understood. Method: Presentation of the dominant mechanisms that prevent CAR T cell activation in solid tumors and strategies to overcome these obstacles. Results: Preclinical research on tumor models and clinical trials in recent years have shown that CAR T cell activation is effectively suppressed in many solid tumors by the prevention of T cell penetration into the tumor as well as active suppression of T cell functions and metabolic conditions that limit T cell survival within the tumor. To overcome these obstacles, various strategies are being tested experimentally and clinically, such as pretreatment of tumors, increasing T cell resistance to suppressive cytokines and metabolites as well as activation of resident immune cells by CAR-mediated release of therapeutically effective cytokines (T cells redirected for unrestricted cytokine-mediated killing, TRUCK). Conclusion: There is considerable developmental potential to make CAR T cell treatment effective against solid tumors. Novel strategies that use CAR T cells as "biopharmaceutical factories" (TRUCK) to selectively activate natural killer (NK) cells and macrophages in tumor tissues recently entered the clinical trial stage.
| Item Type: | Other |
|---|---|
| Uncontrolled Keywords: | THERAPY; CD19; CAR T cell migration; T cells redirected for unrestricted cytokine-mediated killing (TRUCK); Adoptive immunotherapy; T cell activation; Allogeneic CAR T cells; CAR T cell migration; T cells redirected for unrestricted cytokine-mediated killing (TRUCK); Adoptive immunotherapy; T cell activation; Allogeneic CAR T cells |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Immunologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 23 Sep 2026 06:17 |
| Last Modified: | 23 Sep 2026 06:17 |
| URI: | https://pred.uni-regensburg.de/id/eprint/66824 |
Actions (login required)
 |
View Item |
